A non-comparative multi-center randomized phase II study of nivolumab +/− ipilimumab for patients with metastatic sarcoma (Alliance A091401)

BACKGROUND: Metastatic sarcoma patients have limited options. Nivolumab and ipilimumab are monoclonal antibodies targeting PD-1 and CTLA-4, respectively. We evaluated the efficacy and safety of nivolumab and nivolumab plus ipilimumab separately in sarcoma patients. METHODS: We did an open-label, unb...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Lancet Oncol
Main Authors: D’Angelo, Sandra P., Mahoney, Michelle R., Van Tine, Brian A., Atkins, James, Milhem, Mohammed M., Jahagirdar, Balkrishna N., Antonescu, Cristina R., Horvath, Elise, Tap, William D., Schwartz, Gary K., Streicher, Howard
Formato: Artigo
Idioma:Inglês
Publicado: 2018
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6126546/
https://ncbi.nlm.nih.gov/pubmed/29370992
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(18)30006-8
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares